iRadimed IRMD Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $23.61M+5.0% | $22.48M+6.1% | $21.18M+2.6% | $20.66M+4.4% | $19.78M+2.9% | ||
| $1.43M+22.4% | $1.17M+18.9% | $980.53K+23.4% | $794.38K+1.1% | $785.91K-3.9% | ||
| $2.78M-4.9% | $2.92M+1.4% | $2.88M+1.3% | $2.84M+4.5% | $2.72M+7.8% | ||
| -$2.46M+9.8% | -$2.73M-834% | -$291.82K— | —— | —— | ||
| -$29K+65.5% | -$84K+3.1% | -$86.73K+40.8% | -$146.42K-104% | -$71.79K+24.4% | ||
| —— | —— | —— | —— | —— | ||
| $1.84M+28.9% | $1.43M+443% | -$416.88K+75.1% | -$1.68M+42.5% | -$2.91M+6.8% | ||
| -$408K-437% | -$76K-255% | $48.89K— | —— | —— | ||
| —— | —— | —— | —— | $122.88K-87.7% | ||
| $617K+367% | $132K-11.0% | $148.26K-83.6% | $906.3K+3,278% | -$28.52K-109% | ||
| —— | —— | —— | —— | -$225K-125% | ||
| $1.35M-15.2% | $1.6M+11.8% | $1.43M+15.5% | $1.24M— | —— | ||
| —— | —— | —— | —— | -$5.54K+99.3% | ||
| $28.95M+16.0% | $24.95M-0.3% | $25.01M-7.8% | $27.14M+4.3% | $26.03M+1.6% | ||
| $4.47M-42.4% | $7.77M-24.3% | $10.26M-20.7% | $12.93M+13.1% | $11.43M+42.8% | ||
| —— | —— | —— | —— | —— | ||
| -$4.97M+40.9% | -$8.42M+23.9% | -$11.06M+19.9% | -$13.81M-12.7% | -$12.26M-39.0% | ||
| $15.43M+2.6% | $15.04M+79.3% | $8.39M+3.2% | $8.12M+3.3% | $7.86M-42.5% | ||
| $2.5M-2.6% | $2.56M+227% | $784.2K+1.5% | $772.47K+4.4% | $740.12K+7.6% | ||
| -$17.93M-1.9% | -$17.6M-92.5% | -$9.15M-3.1% | -$8.87M-3.5% | -$8.57M+40.2% | ||
| $6.04M+662% | -$1.08M-122% | $4.81M+7.7% | $4.46M-14.3% | $5.2M+111% | ||
| $3.93M+0.1% | $3.92M-13.9% | $4.55M-22.1% | $5.85M-7.6% | $6.33M-2.8% | ||
| -$2.46M+9.8% | -$2.73M-834% | -$291.82K— | —— | —— | ||
| —— | —— | —— | —— | $122.88K-87.7% | ||
| —— | —— | —— | —— | -$225K-125% | ||
| $21.41K-48.3% | $41.41K+33.1% | $31.11K— | —— | —— | ||
| $617K+367% | $132K-11.0% | $148.26K-83.6% | $906.3K+3,278% | -$28.52K-109% | ||
| $2.59M+0.5% | $2.58M+88.9% | $1.36M+631% | $186.4K-68.4% | $589.5K-25.0% | ||
| —— | —— | —— | —— | —— | ||
| $100K+113% | $47K— | —— | —— | —— | ||
| -$29K+65.5% | -$84K+3.1% | -$86.73K+40.8% | -$146.42K-104% | -$71.79K+24.4% | ||
| —— | —— | —— | —— | —— | ||
| $1.35M-15.2% | $1.6M+11.8% | $1.43M+15.5% | $1.24M— | —— | ||
| $3.93M+0.1% | $3.92M-13.9% | $4.55M-22.1% | $5.85M-7.6% | $6.33M-2.8% | ||
| $24.47M+42.4% | $17.18M+16.5% | $14.75M+3.8% | $14.21M-2.7% | $14.6M-17.1% | ||
| $24.47M+42.4% | $17.18M+16.5% | $14.75M+3.8% | $14.21M-2.7% | $14.6M-17.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does iRadimed generate?
- iRadimed (IRMD) generated $28.9M in operating cash flow over the trailing twelve months.
- What is iRadimed's free cash flow?
- After $4.5M of capital expenditures, iRadimed's free cash flow was $24.5M over the trailing twelve months, up 67.6% year over year.
- Where does iRadimed's cash flow data come from?
- Every line is extracted from iRadimed's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
